Medically reviewed by Drugs.com. Last updated on Nov 21, 2019.
Generic name: SOFOSBUVIR 400mg, VELPATASVIR 100mg, VOXILAPREVIR 100mg
Dosage form: tablet, film coated
Testing Prior to the Initiation of Therapy
Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with VOSEVI [see Warnings and Precautions (5.1)].
The recommended dosage of VOSEVI is one tablet, taken orally, once daily with food [see Clinical Pharmacology (12.3)]. One tablet of VOSEVI contains 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir. Table 1 shows the recommended treatment regimen and duration based on patient population.
|Genotype||Patients Previously Treated with an HCV Regimen Containing:||VOSEVI
|1, 2, 3, 4, 5, or 6||An NS5A inhibitor*||12 weeks|
|1a or 3||Sofosbuvir without an NS5A inhibitor†||12 weeks|
Moderate or Severe Hepatic Impairment
VOSEVI is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to higher exposures of voxilaprevir in these patients [see Warnings and Precautions (5.2), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)].
Frequently asked questions
- What types of hepatitis C (HCV) does Vosevi treat?
- What are the new drugs for the treatment of hepatitis C?
- What is the difference between Vosevi and Epclusa?
- How much does Vosevi cost?
- Does Vosevi cure hepatitis C?
More about Vosevi (sofosbuvir / velpatasvir / voxilaprevir)
- Side Effects
- During Pregnancy or Patient Tips
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: antiviral combinations
- FDA Approval History
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.